Latest Fludarabine Stories
SAN FRANCISCO, Dec.
SAN FRANCISCO, Dec.
WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
WHITE PLAINS, N.Y., Dec. 3 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Memgen, LLC jointly announce the beginning of a new clinical trial of ISF35, a cancer vaccine, at the University of California, San Diego (UCSD).
Roche has announced that a Phase III study investigating MabThera in combination with chemotherapy has shown a significant improvement in progression free survival in patients with relapsed or refractory chronic lymphocytic leukemia.
Genentech and Biogen Idec have announced that a global Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone.
By Anonymous United Kingdom - Bayer Schering Pharma AG and Genzyme Europe BV have informed physicians of six infectionrelated deaths, reported from a trial (CALGB10101) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia (CLL) patients were treated with fludarabine and rituximab followed by alemtuzumab for remission consolidation.
COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) to treat two groups of chronic lymphocytic leukemia (CLL) patients with high unmet medical need.
Genmab has completed recruitment of 56 patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat chronic lymphocytic leukemia in previously untreated patients.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.